131 related articles for article (PubMed ID: 15389471)
1. The controversies surrounding the management of uterine serous carcinoma.
Munkarah AR
Cancer; 2004 Nov; 101(10):2152-4. PubMed ID: 15389471
[No Abstract] [Full Text] [Related]
2. Uterine papillary serous carcinoma: what have we learned over the past quarter century?
Goff BA
Gynecol Oncol; 2005 Sep; 98(3):341-3. PubMed ID: 16111527
[No Abstract] [Full Text] [Related]
3. Molecular alterations in uterine serous carcinoma.
Hayes MP; Ellenson LH
Gynecol Oncol; 2010 Feb; 116(2):286-9. PubMed ID: 20109727
[TBL] [Abstract][Full Text] [Related]
4. Uterine papillary serous carcinoma: patterns of failure and survival.
Wang W; DO V; Hogg R; Wain G; Brand A; Bull C; Stenlake A; Gebski V
Aust N Z J Obstet Gynaecol; 2009 Aug; 49(4):419-25. PubMed ID: 19694700
[TBL] [Abstract][Full Text] [Related]
5. Uterine serous and grade 3 endometrioid carcinomas: is there a survival difference?
Boruta DM; Gehrig PA; Groben PA; Bae-Jump V; Boggess JF; Fowler WC; Van Le L
Cancer; 2004 Nov; 101(10):2214-21. PubMed ID: 15452833
[TBL] [Abstract][Full Text] [Related]
6. Metastatic uterine serous carcinoma originating in an endometrial polyp: a report of 2 cases.
Childs AJ; Burke JJ; Perry MY; Gallup DG
J Reprod Med; 2005 Mar; 50(3):209-12. PubMed ID: 15841935
[TBL] [Abstract][Full Text] [Related]
7. Role of surgical staging and adjuvant treatment in uterine serous carcinoma.
Frey MK; Bashir S; Ward NM; Hensel KJ; Caputo TA; Holcomb KM; Baergen R; Gupta D
Eur J Gynaecol Oncol; 2013; 34(5):453-6. PubMed ID: 24475582
[TBL] [Abstract][Full Text] [Related]
8. Patients with uterine papillary serous cancers may benefit from adjuvant platinum-based chemoradiation.
Kelly MG; O'Malley D; Hui P; McAlpine J; Dziura J; Rutherford TJ; Azodi M; Chambers SK; Schwartz PE
Gynecol Oncol; 2004 Dec; 95(3):469-73. PubMed ID: 15581948
[TBL] [Abstract][Full Text] [Related]
9. [Uterine papillary serous carcinoma].
Langmár Z; Németh M; Kornya L
Orv Hetil; 2011 Jul; 152(30):1206-8. PubMed ID: 21733794
[No Abstract] [Full Text] [Related]
10. Outcome after combined modality treatment for uterine papillary serous carcinoma: a study by the Rare Cancer Network (RCN).
Goldberg H; Miller RC; Abdah-Bortnyak R; Steiner M; Yildiz F; Meirovitz A; Villà S; Poortmans PM; Azria D; Zidan J; Ozsahin M; Abacioglu U; Gold DG; Amit A; Lavie O; Atahan IL; Kuten A;
Gynecol Oncol; 2008 Feb; 108(2):298-305. PubMed ID: 18096209
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous metastasis of uterine papillary serous carcinoma presenting as a solitary nodule on the umbilical area.
Lee WJ; Kang SM; Won CH; Chang SE; Lee MW; Choi JH; Moon KC
Acta Derm Venereol; 2009; 89(5):544-5. PubMed ID: 19734994
[No Abstract] [Full Text] [Related]
12. Serous EIC as an early form of uterine papillary serous carcinoma: recent progress in understanding its pathogenesis and current opinions regarding pathologic and clinical management.
Zheng W; Schwartz PE
Gynecol Oncol; 2005 Mar; 96(3):579-82. PubMed ID: 15721397
[No Abstract] [Full Text] [Related]
13. Novel targeted therapies in uterine serous carcinoma, an aggressive variant of endometrial cancer.
Menderes G; Clark M; Santin AD
Discov Med; 2016 Apr; 21(116):293-303. PubMed ID: 27232515
[TBL] [Abstract][Full Text] [Related]
14. Treatment of early-stage uterine papillary serous carcinoma at Roswell Park Cancer Institute, 1992-2006.
Tchabo NE; McCloskey S; Mashtare TL; Andrews C; Singh AK; Mhawech-Fauceglia P; Odunsi K; Lele S; Jaggernauth W
Gynecol Oncol; 2009 Nov; 115(2):249-56. PubMed ID: 19692115
[TBL] [Abstract][Full Text] [Related]
15. [Mitotic activity in serous adenocarcinoma of the uterine body].
Vasil'eva EV; Belianin VL
Vopr Onkol; 2005; 51(2):206-10. PubMed ID: 16223002
[TBL] [Abstract][Full Text] [Related]
16. A 73-gene proliferative transcriptomic signature predicts uterine serous carcinoma patient survival and response to primary therapy.
Tran LKH; Tran PMH; Mysona DP; Purohit SB; Myers E; Lee WS; Dun B; Xu D; Liu H; Hopkins D; Nechtman J; Scelsi CL; Mittal PK; Kleven D; Wallbillich JJ; Rungruang B; Ghamande S; She JX
Gynecol Oncol; 2020 May; 157(2):340-347. PubMed ID: 32067813
[TBL] [Abstract][Full Text] [Related]
17. Importance of the endometrioid carcinoma subtype and sarcomatous component in uterine carcinosarcoma.
Amant F; Vergote I
Gynecol Oncol; 2004 Apr; 93(1):272-3; author reply 273-4. PubMed ID: 15047252
[No Abstract] [Full Text] [Related]
18. Widespread psammoma body formation arising in the background of a uterine serous carcinoma.
Salmons NA
Int J Surg Pathol; 2014 Feb; 22(1):83-6. PubMed ID: 24284131
[TBL] [Abstract][Full Text] [Related]
19. Human kallikrein 6: a new potential serum biomarker for uterine serous papillary cancer.
Santin AD; Diamandis EP; Bellone S; Soosaipillai A; Cane S; Palmieri M; Burnett A; Roman JJ; Pecorelli S
Clin Cancer Res; 2005 May; 11(9):3320-5. PubMed ID: 15867230
[TBL] [Abstract][Full Text] [Related]
20. Metabolic syndrome affects the long-term survival of patients with non-endometrioid carcinoma of the uterine corpus.
Shou H; Yan K; Song J; Zhao L; Zhang Y; Ni J
Int J Gynaecol Obstet; 2020 Jan; 148(1):96-101. PubMed ID: 31560127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
